Contraception choice for HIV positive women

H S Mitchell, E Stephens

UNAIDS/WHO estimates that 42 million people are living with HIV/AIDS worldwide and 50% of all adults with HIV infection are women predominantly infected via heterosexual transmission. Women with HIV infection, like other women, may wish to plan pregnancy, limit their family, or avoid pregnancy. Health professionals should enable these reproductive choices by counselling and appropriate contraception provision at the time of HIV diagnosis and during follow up. The aim of this article is to present a global overview of contraception choice for women living with HIV infection including effects on sexual transmission risk.

There is wide variation in contraception prevalence worldwide ranging from 8% of women aged 15–49 years in western Africa up to 78% in northern Europe. Female sterilisation (32%), intrauterine devices (22%), and the oral contraceptive pill (14%) account for more than two thirds of all contraceptive practice worldwide. In less developed countries 70% of contraception users rely on female sterilisation and intrauterine devices in part because they are advocated by healthcare services as a result of cost effectiveness in terms of pregnancy prevention and service provision.

Contraception use and compliance is related to the range of methods available, patient choice, prevalent health and religious beliefs, perceptions of method effectiveness, and side effects (for example, women may have less tolerance for heavy and prolonged vaginal bleeding than amenorrhoea"). Correct use of most user dependent methods requires a basic knowledge of reproduction and literacy skills to follow written instructions. In many countries women are unable to make autonomous decisions about their sexual and reproductive health because of political instability within society, lack of economic independence, and prevailing cultural or religious attitudes to women’s rights.

HIV POSITIVE WOMEN AND REPRODUCTIVE HEALTH CHOICES

Female injecting opiate drug users with HIV infection also have lower fertility rates.

In studies of women with HIV infection approximately 70% are sexually active, effective contraception use is variable, and unplanned pregnancy frequently reported. In a cohort of Irish HIV positive women only 57% of the sexually active women used a reliable method of contraception. The French SEROCO study on the impact of HIV diagnosis on sexual and contraceptive behaviour found that of the sexually active women 20% were using no contraception, 24% became pregnant, and 63% of conceptions ended in abortion. In the African DITRAME Project 39% of women with HIV infection used contraceptives; factors significantly related to contraceptive use were marital status and level of education. The incidence of further pregnancy was 16.5 per 100 women years at risk; 50% of these pregnancies were unplanned and one third terminated by abortion, significant determinants of pregnancy were death of the previous child, cessation of breast feeding, and cessation of postpartum amenorrhoea. Lactational amenorrhoea is an important and effective means of child spacing in developing countries. For HIV positive women breast feeding increases the risk of HIV transmission to her infant, which has to be balanced against the cost of artificial feeds and risk of death from gastroenteritis.

Abbreviations: COC, combined contraceptive pill; DMPA, depot medroxyprogesterone acetate; HAART, highly active antiretroviral therapy; IUDs, intrauterine devices; LNG-IUS, levonorgestrel intrauterine system; NNRTIs, non-nucleotide reverse transcriptase inhibitors; PID, pelvic inflammatory disease; Ps, protease inhibitors; POP, progestogen only pill.
in the United Kingdom during 2002 and very few infants only 720 pregnancies in HIV positive women were confirmed.

A high degree of protection against HIV sexual transmission is provided by consistent correct condom use; inconsistent or incorrect use is not protective. Most global HIV transmission occurs because condoms are not used at all during sexual intercourse. Condom accidents are reported by 1–12% of users and the method contraceptive failure rate is at least 12%. Dual protection, the simultaneous use of an effective contraception method with consistent condom use, has been advocated to reduce the risk of unplanned pregnancy, horizontal transmission of HIV to a non-infected partner, transmission of resistant virus to an partner with HIV infection, and the risk of acquisition of other STIs including high risk human papillomavirus (HPV) types.

The female condom

The female condom is a polyurethane sheath with two flexible rings at each end; one ring is inserted into the upper vagina and the other covers the introitus. The female condom is less likely than male condoms to leak or break during sex, but intrusion of the outer ring into the vagina is reported in 2% of coital episodes. The cumulative probability of vaginal exposure to semen with female condom use has been estimated as 3%, compared to 11.6% with the male condom. The contraceptive failure rate is estimated at 5–21% over 12 months.

Diaphragms, vumiles, and caps

Diaphragms and vumiles cover the cervix and parts of the vaginal wall, while caps cover only the cervix. Their use in discordant couples is not recommended, as a relatively large area of vaginal mucosa remains exposed, microtrauma during insertion, and the concomitant use of nonoxynol-9 spermicide may cause epithelial disruption and increase viral transmission risk to the male partner.

FACTORS AFFECTING CONSISTENT CONDOM USE

In the WIHS cohort study, in which the HIV status of sexual partners is not known, 60% of women with HIV infection used condoms consistently (“always” versus “sometimes or never”). Consistent use was associated with having one partner, greater income, no illicit drug use and when condoms were the only contraceptive method used.

Women who also use, effective or long term methods of contraception are less likely to report consistent condom use. Condom use is also related to whether the woman has informed her partner of her status; less consistent use is reported by concordant couples, even within discordant partnerships consistent condom use is reported by only approximately 50% couples.

Obstacles to greater use of male condoms include lack of availability, fear of being perceived as having multiple partners and being unfaithful to a regular partner, opposition on religious grounds, and male dominance in decision making. Women living with HIV infection may feel unable to disclose their HIV status and negotiate condom use with new sexual partners for fear of abandonment, domestic violence, loss of economic support, and social isolation.

The issues around female condom use are also negotiating barrier method use, method acceptability by users, and

<table>
<thead>
<tr>
<th>Table 1</th>
<th>Contraception methods</th>
</tr>
</thead>
<tbody>
<tr>
<td>Barrier</td>
<td>Male condom</td>
</tr>
<tr>
<td></td>
<td>Female condom</td>
</tr>
<tr>
<td>Oral hormonal</td>
<td>Diaphragms, cervical caps, vumiles</td>
</tr>
<tr>
<td>Combined contraceptive pill (CCP)</td>
<td></td>
</tr>
<tr>
<td>Progestagen only pill (POP)</td>
<td></td>
</tr>
<tr>
<td>Progestagen only injectables</td>
<td>Depot medroxyprogesterone acetate (DMPA)</td>
</tr>
<tr>
<td>Nonhisterone enanthate (Noristeron, NET-EN)</td>
<td></td>
</tr>
<tr>
<td>Combined injectables</td>
<td>Medroxyprogesterone acetate and estradiol cipionate (Cyclafem, Cycloprovera, Lunelle)</td>
</tr>
<tr>
<td>Norprogeston (Noripol)</td>
<td></td>
</tr>
<tr>
<td>Combined transdermal implants</td>
<td>Evra patch</td>
</tr>
<tr>
<td>Implanon-1 rod etonorgestrel</td>
<td></td>
</tr>
<tr>
<td>Jadelle-2 rods levonorgestrel</td>
<td></td>
</tr>
<tr>
<td>Intrauterine devices</td>
<td>Copper bearing IUDs (Cu-IUD)</td>
</tr>
<tr>
<td>Levonorgestrel intrauterine system (LNG-IUS)</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Table 2</th>
<th>Factors affecting contraception choice for HIV positive women</th>
</tr>
</thead>
<tbody>
<tr>
<td>Country of residence</td>
<td>Access to healthcare services, methods available, and cost</td>
</tr>
<tr>
<td>Religious, cultural, and personal beliefs</td>
<td>Role of woman in society, acceptability to partner, effects on menstrual cycle</td>
</tr>
<tr>
<td>HIV status of woman</td>
<td>CD4 count, viral load, physical wellbeing</td>
</tr>
<tr>
<td>HIV serostatus of partner</td>
<td>Concordant, discordant, not known</td>
</tr>
<tr>
<td>Menstrual, sexual, and reproductive history</td>
<td>Menorrhagia, dysmenorrhea, past pelvic infection, past ectopic pregnancy, pregnancy planning</td>
</tr>
<tr>
<td>Medical history</td>
<td>Abnormal liver function, past history of venous thromboembolic disease, hypertension, hyperlipidaemia, current drug abuse</td>
</tr>
<tr>
<td>Medications</td>
<td>Drug interactions, side effects</td>
</tr>
</tbody>
</table>

The World Health Organization estimates that half a million women die annually from complications of pregnancy, childbirth, or abortion; 90% of these deaths occur in sub-Saharan Africa and Asia where there is significant unmet need for contraception provision. The risks of unplanned pregnancy for women with HIV infection are compounded by the risk of mother to child HIV transmission, which occurs in 30–40% of pregnancies when interventions to reduce vertical transmission, particularly antiretroviral therapy, are not available. In several areas of southern Africa approximately 30% of women attending antenatal clinics are infected with HIV-1. Across Africa around 1900 children acquire HIV-1 infection from their mother every day and three million children under 15 years are living with HIV. In contrast, 30% of women attending antenatal clinics are infected with HIV-1. Across Africa around 1900 children acquire HIV-1 infection from their mother every day and three million children under 15 years are living with HIV. In contrast, 30% of women attending antenatal clinics are infected with HIV-1. Across Africa around 1900 children acquire HIV-1 infection from their mother every day and three million children under 15 years are living with HIV.
higher cost compared with the male condom. The WHO consultation on reuse suggested that female condoms still meet manufacturing quality assessment specifications after seven cycles of bleach disinfections, washing, drying, and relubrication. This protocol has not been evaluated for safety and efficacy in human use and the WHO does not recommend or promote reuse of female condoms and is currently sponsoring research to evaluate reuse protocols under local conditions.

SPERMICIDES
Nonoxynol-9 (N-9) spermicide provides no protection against sexually transmitted infections including HIV and frequent use increases the risk of HIV acquisition. A WHO Contraceptive Research and Development (CONRAD) technical consultation concluded that N-9 should not be used or promoted for the prevention of HIV in women at high risk of infection.

There are no published studies on the female-male transmission risk with N-9 use by women with HIV infection. It seems advisable for women with HIV infection with a discordant sexual partner to avoid N-9 spermicidals alone or with other contraceptive methods to reduce the possible risk of HIV sexual transmission. There is no evidence that condoms lubricated with N-9 are more effective in preventing pregnancy than condoms lubricated with silicone. However, where choice is limited it is better to use any condom than no condom at all. In the future, effective and acceptable microbicides may have a role, providing HIV positive women unable to negotiate consistent condom use with a discordant partner with an additional method to reduce sexual transmission.

HORMONAL CONTRACEPTION

Combined oral contraception (COC)
The combined oral contraceptive pill is an effective user dependent contraception with the non-contraceptive benefits of cycle control, reduction in menorrhagia and dysmenorrhea. Absorption can be affected by prolonged intercurrent diarrhoea and vomiting. The COC is metabolised by the liver and its use is contraindicated in women with abnormal liver function, which may be caused by alcohol abuse, acute or chronic viral hepatitis, and adverse events on antiretroviral combinations. These factors are particularly relevant when making contraception choices for HIV positive women who are current or previous injecting drug users with chronic active hepatitis C infection. Current drug users often have a chaotic lifestyle that precludes effective use of user dependent contraception methods.

Progestogen only pills (POP)
Progestogen only methods may be used by women with contraindications to oestrogen use. The POP is an effective contraceptive method with correct and consistent use; ovulation is not inhibited in all users, and inconsistent use can result in pregnancy. A new progestogen only pill, Cerazette, which contains 75 μg desogestrel, has recently been introduced. In studies Cerazette inhibited ovulation in 97% of cycles at 7 and 12 months after initiation; this would suggest enhanced efficacy in comparison with conventional POPs, though as yet unconfirmed by comparative trials.

Long acting progestogen only contraception
Injectables
Depot medroxyprogesterone acetate (DMPA) 150 mg is given by deep intramuscular injection at 12 weekly intervals and norethisterone enanthate (Noristerat) 200 mg every 8 weeks. These methods have the advantage of not being intercourse related but require regular access to health care for repeat injections.

Implants
Implants need to be inserted by a trained health professional. Implanon is effective for 3 years, and Jadelle for 5 years (not licensed in the United Kingdom); both are highly effective, non-user dependent, and reversible methods of progestogen only contraception.

Combined injectables and patches
Combined injectables are used in some developing countries and in the United States. The weekly combined contraceptive patch (EVRA) is now licensed in some countries but availability is limited by cost. Transdermal delivery systems bypass first pass liver metabolism; this may reduce effects on clotting factors but the influence on risks of venous thrombosis and embolism is not currently known.

HORMONAL CONTRACEPTION AND HIV SEXUAL TRANSMISSION

The vaginal epithelium as a barrier
Studies and review articles have tried to address the question of whether hormonal contraception increases the risk of HIV acquisition in women. Many of these studies had methodological deficiencies owing to difficulty in overcoming confounding between sexual risk taking and choice of contraceptive method when using retrospective data. A large observational cohort study in Uganda recently reported that, after adjustment for behavioural confounding, hormonal contraception use was not associated with an increased risk of HIV acquisition in women. However, in this study more married women self selected to hormonal methods and use was based on self reporting.

There is evidence that sexual transmission risk is related to the infected individual’s HIV status—for example, CD4 count, plasma HIV-1 RNA levels. Acquisition and transmission of HIV is increased in the presence of genital tract inflammation and ulceration. It is not known whether hormonal contraception use by HIV positive women, while effectively preventing unplanned pregnancy and thus vertical transmission, leads to an increased risk of transmission to sexual partners. A concern arising from macaque monkey studies is whether long acting progestogens, by inducing an anovulatory state with vaginal epithelium thinning, reduce the efficacy of the vaginal barrier. This barrier effect could increase the risk of HIV acquisition and sexual transmission in women. The presence of a cervical ectropion in association with combined hormonal contraception use has also been suggested as a risk factor for sexual HIV acquisition and transmission. Mostad et al reported that use of oral contraceptives and the 3 monthly injectable DMPA may be associated with increased shedding of HIV-1 infected cells from the cervix and vagina but they did not measure other parameters of infectivity such as free HIV-1 virions or cell associated HIV-1 RNA.

Effective HAART regimens, which result in undetectable plasma HIV-1 RNA, effectively and rapidly reduce infectivity of genital secretions and sexual transmission risk. However, there is also evidence that plasma HIV-1 RNA may not correlate directly with genital HIV-1 RNA. Genital shedding was demonstrated in 25% of women with an undetectable viral load in one recent study. This suggests that the genital tract should be regarded as a distinct compartment with regard to viral replication, and that plasma viral loads may not predict genital viral shedding especially in the presence of genital tract inflammation and ulceration. The additional effect of contraception methods on genital viral shedding and sexual transmission risk is uncertain. One study reported no
The universities of California and Zimbabwe are conducting a multisite longitudinal observational study of HIV-1 genital shedding and the effect of hormonal contraception on the parameters of infectivity of women with HIV infection.

**Menstruation and irregular vaginal bleeding**

Irregular vaginal bleeding is common in the first 3 months of DMPA use. Over time the frequency of bleeding reduces. By 1 year approximately 50% of users will have complete amenorrhoea during at least one injection cycle, this increases to 68% by 24 months. Heavy or prolonged bleeding and amenorrhoea are less common in NET-EN users. Implanon induces anovulation and amenorrhoea is reported by 30–40% of users by 12 months; menstrual irregularity with frequent or prolonged bleeding can occur in about 10% of users with discontinuation rates of 11.7% by 12 months. The menstrual irregularities and prolonged bleeding induced by progestogen only contraceptives could increase the risk of sexual transmission during unprotected sex.

Some women, especially those with heavy or painful menstruation, may welcome amenorrhoea but there are cultural variations in acceptability and this issue should be discussed during counselling. Tricycling or continuous use of combined oral contraception, while an unlicensed use, can eliminate monthly menstruation for HIV positive women; however, this objective can also be satisfactorily achieved over time with DMPA.

**INTRAUTERINE DEVICES**

**Copper bearing intrauterine devices**

Copper bearing intrauterine devices (IUDs) are highly effective, long term (the Safe-T 380 is licensed for 8 years of use) and cost effective methods of contraception.

**Levonorgestrel intrauterine system**

The levonorgestrel intrauterine system (LNG-IUS) is highly effective with a failure rate of 0.1–0.2 per 100 women years and is licensed for 5 years. The LNG-IUS has a lower rate of ectopic pregnancy (0.06 per 100 women years) and there is some evidence of a lower risk of pelvic inflammatory disease compared to copper bearing IUDs. The local action of LNG-IUS results in endometrial thinning and irregular vaginal bleeding can occur in the first 3 months of use. By 12 months there is a 94–97% reduction in menstrual loss with amenorrhoea in 10–15% of users, which is beneficial for women with dysmenorrhea and menorrhagia with associated iron deficiency anaemia.

**INTRAUTERINE DEVICE USE BY WOMEN WITH HIV**

The WHO medical eligibility criteria caution against IUD and LNG-IUS use by women at risk of HIV, HIV positive women, and women with AIDS. This is a grade 3 criterion “theoretical or proved risks generally outweigh the advantages” as opposed to grade 4 which is an “unacceptable health risk.” There are a number of concerns about IUD use by women with HIV infection relating to contraceptive efficacy, risks of sexual transmission, and acute pelvic inflammatory disease (PID).

The theoretical risk of decreased contraceptive efficacy caused by reduced endometrial inflammatory response in advanced immunosuppression, is based on reports of IUD failures in renal transplant patients. A review of IUD failures concluded that reports of increased failure in women on steroids and anti-inflammatory drugs were not convincing and that the copper content of IUD types used was more significant. Sexual transmission of HIV in IUD users may be increased as a result of increased volume and duration of menses, genital inflammation, and microtrauma to the penile epithelium by the IUD threads. In a study of 98 HIV positive women in Kenya, using PCR of HIV-1 gag DNA sequences, there was no statistically significant change in cervical shedding of HIV-1 DNA at 4 months after IUD insertion. Within a cohort study, which included a small subgroup of male partners of HIV positive IUD users, female to male transmission was significantly increased with advanced stage of HIV infection and unprotected sex during menses and reduced by consistent condom use.

There is a sixfold increase in risk of acute PID during the first 20 days after IUD insertion, after which PID is uncommon (1.6 per 1000 women years) except in the presence of an undiagnosed STI—for example, Chlamydia trachomatis. A randomised trial investigating antibiotic prophylaxis at the time of IUD insertion concluded that routine prophylaxis is not warranted. However, this study used follow up attendance to assess IUD complication and removal rates in a population of unscreened women considered to be at low risk of sexually transmitted infection. High prevalence of HIV is known to be associated with high prevalence of other sexually transmitted infections. Routine testing, or antibiotic prophylaxis, for C trachomatis is recommended before elective IUD insertion in the United Kingdom. These tests may not be available in developing countries. In a prospective study on 156 HIV-1 positive and 493 HIV negative unscreened women in Kenya, complication rates including pelvic inflammatory disease and removal because of pain or bleeding were similar in both groups.

When the need for effective contraception is paramount—for example, legal abortion is unavailable, teratogenic drug therapy, and choice of available methods limited, a copper bearing IUD should be offered to HIV positive women at risk of unplanned pregnancy. Selection criteria could include monogamous relationship, negative sexually transmitted infection screen, no past history of ectopic pregnancy or PID, CD4 counts >200 (if available), and continuing access to medical services.

Where the LNG-IUS is available the additional non-contraceptive benefits and lower failure rate make it the preferred intrauterine method; we routinely offer this option to HIV positive women.

**MALE AND FEMALE STERILISATION**

Male and female sterilisation are both effective “permanent” cost effective methods of contraception. Male sterilisation has a failure rate of 1:2000 compared to 1:200 for female sterilisation. Sterilisation procedures do not reduce HIV in genital secretions nor the risk of sexual HIV transmission and it is worrying that studies show a reduction in consistent condom use in couples after one partner has undergone sterilisation.

**EMERGENCY CONTRACEPTION**

Emergency contraception is currently available as Levonelle-2 (Levonelle is an identical over the counter product) comprising two tablets of 750 µg levonorgestrel (LNG). This is most effective when taken within the first 24 hours of unprotected sexual intercourse but can be taken up to 72 hours after unprotected sexual intercourse. A recent WHO study concluded that a single 1.5 mg dose is as effective as the standard two dose regimen. The product licence has now been changed to reflect this and the new Levonelle pack has become available in the United Kingdom in 2004.

Women using condoms alone for contraception must be advised about emergency contraception. In a study of HIV positive women attending an inner London HIV outpatient
unit, 47% of women were aware of emergency contraception, but only 37.7% had correct information about where to obtain supplies and how to use it.81

**CONTRACEPTION**

**DRUG INTERACTIONS AND HORMONAL CONTRACEPTION**

**Enzyme inducers**

**Antiretroviral therapy**

Ethinyl oestradiol and progestogens are both substrates of the cytochrome p450 CYP 3A4 system of enzymes present in the microsomal system of hepatocytes in the liver and enterocytes in the small intestine. Antiretroviral drugs that induce cytochromes—for example, ritonavir, nevirapine, increase the hepatic metabolism of hormonal contraception. Inhibitors cause decreased clearance and increased plasma concentrations of substrate drugs. When both drugs are substrates their interaction is more uncertain and may result in increased or decreased plasma concentrations. Some drugs exhibit two or all three of these properties—for example, efavirenz.82

Most of the evidence on antiretroviral drug interactions is based on pharmaceutical industry sponsored research with studies using plasma levels to give a measure of total exposure and assess interactions with oral ethinyl oestradiol and norethindrone (table 3). There is no information on antiretroviral interactions in long term contraception use, their effects on contraceptive efficacy (failure rate per 100 women years), and interactions with other hormonal methods.

Indinavir is a CYP3A4 inhibitor; the product information advises that no contraceptive dose modification is required.83 The nucleoside analogues stavudine and didanosine are not p450 enzyme inducers, there are no data on interactions but they are not expected to interact with oral hormonal contraceptives.84

Physicians prescribing contraception can access the following useful websites for current information on antiretroviral drug interactions: www.hiv-druginteractions.org; www.hivinsite.ucsf.edu/arvdb; and www.projinf.org/fs/drugin.html.

**Other important enzyme inducers**

Other important CYP3A enzyme inducers which may be prescribed for women with HIV infection include rifampicin (Mycobacterium tuberculosis) and rifabutin (Mycobacterium avium intracellulare) Both drugs are highly potent inducers recognised to cause hormonal contraception failure and reduced efficacy up to 4 weeks after treatment ends.85

Other important enzyme inducing drugs include griseofulvin, tolbutamide and the anticonvulsants phenobarbitone, carbamazepine, phenytoin, primidone, and topiramate. Patients who buy St John’s Wort (Hypericum perforatum) over the counter to treat mild depression should be advised this is an enzyme inducer that may cause breakthrough bleeding and in theory reduced efficacy of oral hormonal contraceptives.86

<table>
<thead>
<tr>
<th>Table 3</th>
<th>Antiretroviral enzyme inducers that may reduce efficacy of oral hormonal contraceptives</th>
</tr>
</thead>
<tbody>
<tr>
<td>Protease inhibitors (PIs)</td>
<td>Ritonavir87</td>
</tr>
</tbody>
</table>

**Contraception management**

Women taking enzyme inducing drugs should be advised there is a risk of reduced efficacy of the COC and consideration given to other methods of contraception. If, after counselling, the woman wishes to continue the COC a 50 µg ethinyl oestradiol dosage should be used. This can also be achieved by doubling up on lower dose pills—for example, Femodone 50 µg plus one Femodette 20 µg each day. There is no evidence that efficacy is further increased by tricycling (taking three consecutive packs of COC) with 4 pill free days.87 88

There is no evidence on the interaction of enzyme inducing antiretroviral drugs with the other hormonal contraception methods. Taking the pragmatic view prescribers could apply current advice for women taking other enzyme inducing drugs.

- Women on the progestogen only pill should be advised to change to a long acting injectable progestogen or another form of contraception.
- It is common practice to reduce the injection interval for DMPA from 12 to 10 weekly but the summary of product characteristics states that no adjustment is necessary.89

**Overview**

- Women with HIV infection, like other women, may wish to plan pregnancy, limit their family, or avoid pregnancy. Health professionals should enable these reproductive choices by counselling and appropriate contraception provision at the time of HIV diagnosis and during follow up.
- Lactational amenorrhoea is an important and effective means of child spacing in developing countries. HIV positive women avoid breast feeding and will recommence ovulatory cycles earlier; their future contraception needs should be discussed during pregnancy or early in the postnatal period.
- Condoms have a significant user and method failure rate. Dual protection, the simultaneous use of an effective contraception method with consistent condom use, is recommended for effective prevention of unplanned pregnancy and HIV sexual transmission. Women continuing to use condoms alone must be advised how to access emergency contraception.
- Oral, injectable, and implantable hormonal contraception methods and the intrauterine system are all suitable choices for HIV positive women without medical contraindications to their use—for example, hepatitis C related liver disease.
- Caution may be required in prescribing hormonal contraception for women taking enzyme inducing drugs including some HAART and anti-TB agents.
- For HIV positive women with more advanced disease, menorrhagia or irregular menstrual cycles, and current injecting drug users the Mirena (LNG-IUS) system and injectable progestogens could be recommended as they both reduce user dependency and menstrual loss.
- Male and female sterilisation should not be forgotten both are effective “permanent” cost effective methods of contraception. Women should be given the opportunity during pregnancy to consider sterilisation at the time of their elective caesarean section delivery.
As the main mode of action of the LNG-IUS is a direct local effect on the endometrium this may be less affected by liver enzyme induction. A pilot study in 56 women using the LNG-IUS while taking enzyme inducing drugs, predominantly anti-epileptic drugs, showed no reduction in efficacy.35

Women using the subdermal implant may experience breakthrough bleeding and Implanon contraceptive efficacy is reduced.36 They should be advised to change to a long acting injectable progestogen or to consistently use condoms as additional protection.

Women using the combined hormonal patch should be advised to change to a long acting injectable progestogen or another form of contraception.

There is little evidence on the effect of enzyme inducers on progestogen only emergency contraception; current advice is to take two tablets (1.5 mg dose) followed 12 hours later by one tablet (750 μg dose).37 A copper IUD containing >300 mm² can be inserted up to 5 days after the expected date of ovulation in a regular menstrual cycle and may be used for multiple episodes of unprotected sexual intercourse and may be the preferred option for women on liver enzyme inducers after testing for sexually transmitted infection and/or routine antibiotic prophylaxis.

**Broad spectrum antibiotics**

Broad spectrum antibiotic use—for example, tetracyclines and penicillins, in women taking the combined oral contraceptive pill may affect gut bacteria and enterohepatic recirculation of ethinyl oestradiol. Although the failure rate is within the range associated with typical use caution is advised as some women may have significant decreases in plasma levels of ethinyl oestradiol.38 Additional consistent condom use should be advised for the duration of antibiotic treatment and for 7 days after, if the last 7 days of the pill pack are involved the next pill free interval should be omitted. This precaution is not necessary with the combined contraceptive patch, EVRA, as transdermal administration bypasses the enterohepatic cycle.

**Authors’ affiliations**

H S Mitchell, Mortimer Market Centre, Camden Primary Care Trust, London, UK

E Stephens, Margaret Pyke Centre, Camden Primary Care Trust, London, UK

**REFERENCES**


2 International Planned Parenthood Federation. IMAP statement on hormonal methods of contraception. IPPF Medical Bulletin 2002;366:No 5 Oct


4 UNICEF. Contraceptive use and contraceptive use 2000.


7 Gazmarchian JA, Parker RM, Baker DW. Reading skills and family planning knowledge and practices in a low-income managed-care population. Obstet Gynaecol 1999;93:239-44.


29 International Planned Parenthood Federation (IPPF). International Medical Advisory Panel (IMAP) statement on dual protection against unwanted pregnancy and sexually transmitted infections, including HIV. IPPF Medical Bulletin 2000;34:No 4 Aug.


Contraception choice for HIV positive women

48 WHO. Medical eligibility criteria for contraceptive use, 2nd ed. Available for download on the internet at www.who.int/reproductive-health/publications/RHR_00_2_medical_eligibility.cr


84 Hoffman-La Roche Ltd, Basle, Switzerland/Aguonum Pharmaceutical Inc, La Jolla, USA. Data on file: Viracept (nelfinavir mesylate), Study AG. 1343–526.


87 Sue N. Senior Medical Information Pharmacist, Bristol-Myers Squibb Pharmaceuticals Ltd. Medical Information Dept. Personal communication, Feb, 2003.


90 Breckenridge A. Important interactions between St John’s Wort (Hypericum perforatum) preparations and prescribed medicines. London: Committee on Safety of Medicines, 29 Feb 2000.


www.stijournal.com